Education
About Us
Working with TipRanks
Follow Us
NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ:NTHI
NTHI Stock Chart & Stats
$8.88
--
Market closed
$8.88
--
Day’s Range― - ―
52-Week Range$3.20 - $25.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)103.40K
Market Cap
$203.78M
Enterprise Value$173.08M
Total Cash (Recent Filing)$1.51M
Total Debt (Recent Filing)$378.74K
Price to Earnings (P/E)―
Beta1.76
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,692,160
10 Day Avg. Volume39,098
30 Day Avg. Volume103,402
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)-32.79
Price to Sales (P/S)2174.97
P/FCF Ratio-42.84
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue2.89K
Enterprise Value/Gross Profit4.15K
Enterprise Value/Ebitda-3.25
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising Clinical Efficacy Of NEO100Phase 1/2a updates showing meaningful radiographic remissions and durable progression-free survival point to NEO100’s potential as a differentiated, CNS-penetrant therapy. If confirmed in larger trials, this creates a sustainable clinical and commercial advantage in a high unmet-need oncology niche.
Strategic Partnership And Non-dilutive FundingA $50M partnership plus NIH grant provides substantial capital and strategic validation, enhancing development funding and access to resources. Such commitments materially reduce execution risk and support trial advancement and commercialization capacity over the medium term.
Marked Reduction In Reported DebtSharp debt reduction meaningfully lowers leverage and interest pressure, improving financial flexibility. This structural balance-sheet improvement strengthens the company’s ability to fund R&D and operations without immediate solvency risk, supporting longer-term execution.
Bears Say
Large, Persistent Net LossesSustained, sizable net losses reflect a cost base far above current revenues and erode shareholder capital. Over time, continued losses can impair strategic flexibility, necessitate frequent funding, and complicate the path to sustainable profitability even with promising clinical data.
Worsening Operating Cash BurnIncreasing negative operating and free cash flow constrains runway and forces reliance on external capital. Structurally, persistent cash burn pressures R&D pacing and may necessitate dilution or partnership trade-offs if revenue scaling does not materialize within the next funding cycle.
Ongoing Dependence On Equity FinancingsRepeated equity financings signal reliance on capital markets to sustain operations. While financings provide liquidity, they increase dilution risk and reflect that the business is not yet self-funding; long-term investor returns depend on successful clinical commercialization or sustained revenue growth.
NeOnc Technologies Holdings, Inc. News
NTHI FAQ
What was NeOnc Technologies Holdings, Inc.’s price range in the past 12 months?
NeOnc Technologies Holdings, Inc. lowest stock price was $3.20 and its highest was $25.00 in the past 12 months.
What is NeOnc Technologies Holdings, Inc.’s market cap?
NeOnc Technologies Holdings, Inc.’s market cap is $203.78M.
When is NeOnc Technologies Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NeOnc Technologies Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is NeOnc Technologies Holdings, Inc. overvalued?
According to Wall Street analysts NeOnc Technologies Holdings, Inc.’s price is currently Overvalued.
Does NeOnc Technologies Holdings, Inc. pay dividends?
NeOnc Technologies Holdings, Inc. does not currently pay dividends.
What is NeOnc Technologies Holdings, Inc.’s EPS estimate?
NeOnc Technologies Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeOnc Technologies Holdings, Inc. have?
NeOnc Technologies Holdings, Inc. has 22,692,160 shares outstanding.
What happened to NeOnc Technologies Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeOnc Technologies Holdings, Inc.?
Currently, no hedge funds are holding shares in NTHI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeOnc Technologies Holdings, Inc. Stock Smart Score
Company Description
NeOnc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Technical Analysis
Ownership Overview
52.43% Insiders
0.45% Mutual Funds
0.18% Other Institutional Investors
46.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---